A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes

NCT05691712 on ClinicalTrials.gov · last registry update 2025-08-08

Finished 1 July 2024, after enrolling 257 people. Primary outcome, as filed: Mean Change From Baseline in HbA1c (Tirzepatide 10 or 15 Milligram [mg]). tirzepatide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P3
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 257
Started: 2023-02-05
Primary completion: 2024-07-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Mean Change From Baseline in HbA1c (Tirzepatide 10 or 15 Milligram [mg])

Conditions studied

Diabetes Type 2 · Diabetes Mellitus · Glucose Metabolism Disorders · Metabolic Disease · Endocrine System Diseases

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.